Search Results
Feb 23, 2026, 09:00 ET Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
treatments through LillyDirect,4 which offers self-pay pricing at a 50% or greater discount compared to the list price of other incretin (GLP-1) medicines for obesity. One out of every three new patients starting a branded weight management medication was prescribed Zepbound self-pay
More news about: Eli Lilly and Company
Feb 20, 2026, 10:00 ET Bounce Back with La Roche-Posay's New Hyalu B5 Suractivated Cream and Serum
rise of GLP-1 weight-loss medications creates new skincare challenges, such as a loss of visible facial plumpness and lack of skin hydration, La Roche-Posay conducted a targeted consumer study on the Hyalu B5 Serum and Cream regimen. The protocol evaluated 112 GLP-1 users, with
More news about: La Roche-Posay
Feb 20, 2026, 06:59 ET GLP China Holdings Limited: ANNOUNCEMENT OF THE RESULTS OF THE OFFER BY THE ISSUER TO THE HOLDERS OF ITS U.S.$700,000,000 2.95 PER CENT. NOTES DUE 2026 (ISIN: XS2314779427; Common Code: 231477942) (Stock Code: 40629) (the "Notes")
announcement shall have the meaning given to them in the Tender Offer Memorandum and the Announcement, as the case may be. On 12 February 2026, GLP Pte. Ltd., the parent and controlling shareholder of the Issuer, successfully settled the issuance of additional U.S. dollar-denominated senior notes
More news about: GLP China Holdings Limited
Feb 19, 2026, 20:48 ET Prism Technology Strengthens Global Position with Eco-Friendly, High-Quality Upgraded Ink Line
system based on ISO 9001 and ISO 14001 certificationsVerified human and environmental safety through non-toxicity testing under international GLP standardsDemonstrated export competitiveness by being selected for the "Global Small and Medium Enterprises 1000+" program by Korea's Ministry
More news about: Prism Technology
Feb 19, 2026, 13:05 ET Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?
metabolic benefits.A Revolutionary Mechanism: Targeting the Brain's Reward and Addiction PathwaysUnlike GLP-1 and dual GLP-1/GIP agonists that primarily act on the gut and peripheral systems, and are reducing body weight while causing a lean soft tissue loss,
More news about: Moonage Media
Feb 19, 2026, 10:00 ET Calibrate Completes Transition to Enterprise-Focused Obesity Management, More Than Doubles Client Roster
successful transition reflects accelerating employer demand for weight management solutions as organizations confront rising employee demand for GLP-1 medications, which is driving unpredictable pharmacy spend while raising concerns about whether medication-driven weight loss is sustainable after
More news about: Calibrate Health, Inc
Feb 18, 2026, 09:32 ET True Citrus Launches Innovative True Lemon Wellness Line for Cravings, Immunity and Energy Support
management market is often rife with skepticism. True Lemon Curb helps support those on weight loss or weight maintenance journeys, including GLP-1 protocols or post-protocol, those embracing mindful eating lifestyles like intermittent fasting, Mediterranean or Keto or those looking for help
More news about: True Citrus
Feb 18, 2026, 09:00 ET Goodpath Expands Weight Management to Help Employers Regain Control of GLP-1 Cost, Access, and Clinical Oversight
Exploding GLP-1 demand and opaque PBM pricing have left employers facing unpredictable spend, rigid eligibility rules, and limited visibility into how GLP-1 use grows and changes over timeGoodpath introduces direct-to-employer and self-pay GLP-1 pathways
More news about: Goodpath
Feb 18, 2026, 09:00 ET Goodpath Expands Direct-to-Employer and Self-Pay Access to Wegovy Through Novo Nordisk Collaboration
New DTE and self-pay employer pathways support flexible program design and transparent GLP-1 costs, with clinically-led prescribing and care plansGoodpath's whole-person weight care approach treats the comorbidities that drive total
More news about: Goodpath
Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
arthritis who also have obesity or overweight. Zepbound is the only FDA-approved dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity management medication.Detailed 36-week results from TOGETHER-PsO will be published in
More news about: Eli Lilly and Company
Feb 17, 2026, 09:11 ET NEWBEAUTY'S WINTER 2026 'STATE OF AESTHETICS' REPORT REVEALS TOP COSMETIC PROCEDURE TRENDS
Based on surveys conducted throughout late 2025, the Winter 2026 report highlights how patients are approaching menopause, hair health, GLP-1–related weight loss and preventive care. The findings reflect a clear shift away from one-off procedures toward more personalized, long-term aesthetic
More news about: NewBeauty
Feb 17, 2026, 09:01 ET MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia Inc.
Feb 17, 2026, 08:39 ET Vampire Wing Lift® Addresses "Ozempic Vulva": Weight Loss Drugs Spotlight a 16-Year-Old Solution
loss FAIRHOPE, Ala., Feb. 17, 2026 /PRNewswire/ -- As GLP-1–based weight-loss medications continue to gain popularity, a new term has entered public discussion: "Ozempic vulva," referring to the volume loss,
More news about: Cellular Medicine Association
Feb 17, 2026, 08:00 ET Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device
Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 womenVANCOUVER, BC, Feb. 17, 2026 /PRNewswire/ -- Zero Candida
More news about: Zero Candida
Feb 17, 2026, 08:00 ET Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device
Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 womenVANCOUVER, BC, Feb. 17, 2026 /CNW/ -- Zero Candida Technologies,
More news about: Zero Candida
Feb 17, 2026, 07:00 ET CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
Next-generation rhCollagen-based technology aims to restore facial structure and skin quality in patients experiencing volume depletion linked to GLP-1 weight-loss therapiesREHOVOT, Israel, Feb. 17, 2026 /PRNewswire/
More news about: CollPlant
Feb 17, 2026, 07:00 ET sweelin® is now FDA GRAS Approved, Clearing the Path for Accelerated U.S. Commercialization
sweelin® a unique, high-potential and safe protein sweetener that also fits perfectly with the strong trend of protein-focused and GLP-1-friendly food and beverage innovations. Its Clean Label compatibility adds extra appeal for both manufacturers and consumers."Receiving
More news about: Amai Proteins
Feb 16, 2026, 08:42 ET Hanyang University ERICA Researchers Identify Key Mechanism Driving Progression of Fatty Liver Disease to Cancer
this field."The comprehensive analysis examines therapeutic strategies targeting ER stress pathways, including recently approved GLP-1 receptor agonists, and explores the brain-liver connection in metabolic disease progression. The article further highlights newly identified molecular
More news about: Hanyang University
Feb 15, 2026, 08:00 ET GLP-1s Associated with Reduced Asthma Exacerbation in Patients Without Diabetes
GLP-1 initiation was associated with a reduced risk of exacerbation with a risk ratio of 0.780 and a risk difference of 13.3%.By exploring the effects of GLP-1s in patients without diabetes, this research provides a unique insight into a potential benefit of GLP-1 therapy
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)
Feb 13, 2026, 11:26 ET Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
VK2735 into Phase 3 development in the third quarter of 2026, with maintenance dosing study results also expected in that period. The dual GLP-1/GIP agonist demonstrated up to 14.7% weight loss from baseline in its Phase 2 VENTURE trial.Insulet (NASDAQ: PODD)
More news about: Equity Insider
Feb 13, 2026, 08:31 ET MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
(OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR),
More news about: MetaVia Inc.
Feb 12, 2026, 09:00 ET Open Enrollment Recap: Americans Who Comparison Shopped Medicare Advantage for 2026 Potentially Saved an Average of Over $1,600 Per Year
Medicare beneficiaries (and 54% of adults overall) seeking to lose weight in 2026 want to use GLP-1 drugs to meet their goals.About the survey and Medicare Advantage plan analysis eHealth's survey findings are based
More news about: eHealth, Inc.
Feb 11, 2026, 16:16 ET Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
GLP-1 therapeutics due to tolerability or other reasons. The company has been developing a series of potent agonists of the amylin and calcitonin receptors, which could play an important role as both single agents or in combination with GLP-1 or dual GLP-1/GIP agonists.The
More news about: Viking Therapeutics, Inc.
Feb 11, 2026, 16:01 ET Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
preparing for the NEREUS commercial launch and plan to start a Phase III program in the first half of 2026 for its use in preventing vomiting from GLP-1 analogs," continued Dr. Polymeropoulos. "We submitted the imsidolimab BLA in Q4 2025 for generalized pustular psoriasis, a rare orphan condition.
More news about: Vanda Pharmaceuticals Inc.
Feb 11, 2026, 09:05 ET New Findings Highlight Two Decades of Evidence Supporting Pecans in Heart-Healthy Diets
findings around satiety and weight management add important context, particularly as interest grows in appetite regulation and the use of GLP-1 therapies."Emerging Research AreasThe review identifies promising opportunities for future research:Gut
More news about: American Pecan Promotion Board